Ipamorelin: The Most Selective Growth Hormone Secretagogue
Last updated: April 14, 2026 · 14 min read · Reviewed by Grey Peptides Editorial Board
TL;DR
Ipamorelin is a synthetic pentapeptide (5 amino acids) that stimulates growth hormone release by activating the ghrelin receptor (GHS-R1a) on pituitary somatotroph cells. What sets it apart from other ghrelin mimetics (GHRP-6, GHRP-2, MK-677) is its remarkable selectivity — at doses that produce substantial GH release, it does not significantly elevate cortisol, prolactin, ACTH, or aldosterone. This makes Ipamorelin the cleanest GH secretagogue available, providing the GH benefits without the hormonal side effects that limit other compounds in its class. It is most commonly used in combination with CJC-1295 (no DAC), where the dual GHRH + ghrelin pathway activation produces a synergistic GH pulse. Standard dosing is 200–300 mcg injected subcutaneously at bedtime on an empty stomach.
→ Explore Ipamorelin in the Peptide Encyclopedia.
→ Calculate dosing with the Reconstitution Calculator.
Table of Contents
- What Is Ipamorelin?
- Origin & Development
- Molecular Profile
- Mechanism of Action
- Selectivity: Why It Matters
- Human Clinical Data
- Dosing Protocols
- Reconstitution & Administration
- Side Effects & Safety
- Legal & Regulatory Status
- Ipamorelin vs Other GH Secretagogues
- Stacking Ipamorelin
- Frequently Asked Questions
- Sources
What Is Ipamorelin?
Ipamorelin is a growth hormone secretagogue — a compound that stimulates the pituitary gland to release growth hormone. Unlike exogenous HGH (which introduces external growth hormone directly), Ipamorelin triggers your body to produce and release its own GH through activation of the ghrelin receptor, maintaining natural regulatory feedback mechanisms.
Ipamorelin belongs to the class of growth hormone releasing peptides (GHRPs), which work through the ghrelin/GHS receptor pathway — a completely separate system from the GHRH receptor pathway targeted by compounds like CJC-1295 and sermorelin. The existence of these two independent GH-releasing pathways is what makes CJC-1295 + Ipamorelin stacking so effective.
Developed by Novo Nordisk in the late 1990s, Ipamorelin emerged from the effort to create a ghrelin mimetic with potent GH-releasing properties but without the unwanted hormonal effects of earlier compounds in its class. It achieved this goal definitively — becoming the first and most selective GH secretagogue in the ghrelin mimetic category.
Origin & Development
The discovery of growth hormone secretagogues began in the 1970s when researchers identified synthetic compounds (later understood to mimic ghrelin, which wasn't discovered until 1999) that could stimulate GH release through a pathway independent of GHRH. The first generation — GHRP-6 and GHRP-2 — were effective but raised cortisol, prolactin, and appetite alongside GH, limiting their therapeutic utility.
Ipamorelin was developed by Raun et al. at Novo Nordisk and first published in 1998 in the European Journal of Endocrinology. The researchers systematically screened peptide libraries to identify a compound with maximal GH selectivity — one that would release GH potently without activating the hormonal side-pathways that plagued earlier GHRPs.
The result was a pentapeptide (Aib-His-D-2Nal-D-Phe-Lys-NH₂) with extraordinary selectivity: at doses producing comparable GH elevation to GHRP-6 and GHRP-2, ipamorelin showed no significant increase in cortisol, prolactin, or ACTH. This selectivity profile has made it the preferred ghrelin mimetic for GH optimization protocols.
Novo Nordisk investigated ipamorelin for post-operative ileus (intestinal paralysis after surgery) through Phase 2 clinical trials but did not pursue full regulatory approval for this indication. The compound subsequently became widely used in the research peptide and anti-aging medicine communities.
Molecular Profile
| Property | Value |
|---|---|
| Full name | Ipamorelin acetate |
| Sequence | Aib-His-D-2Nal-D-Phe-Lys-NH₂ |
| Amino acids | 5 (pentapeptide) |
| Molecular weight | ~711.9 Da |
| Half-life | ~2 hours |
| Bioavailability | SubQ injection (oral bioavailability negligible) |
| Target receptor | GHS-R1a (growth hormone secretagogue receptor / ghrelin receptor) |
| GH release onset | 15–30 minutes post-injection |
| GH peak | ~60 minutes post-injection |
| Return to baseline | ~3–4 hours post-injection |
| Storage (lyophilized) | Room temperature stable; refrigeration extends shelf life |
| Storage (reconstituted) | Refrigerate, use within 28 days |
Mechanism of Action
Ipamorelin activates the growth hormone secretagogue receptor type 1a (GHS-R1a), the same receptor that endogenous ghrelin binds. This receptor is distinct from the GHRH receptor — the two represent parallel, independent pathways for stimulating GH release.
The signaling pathway:
- Ipamorelin binds to GHS-R1a on pituitary somatotroph cells
- This activates phospholipase C via Gq/11 signaling
- IP3 is generated, releasing calcium from intracellular stores
- Elevated intracellular calcium triggers exocytosis of GH-containing secretory granules
- GH is released into the bloodstream in a sharp pulse
Why this differs from GHRH signaling: CJC-1295 and other GHRH analogs work through the cAMP/PKA pathway (via Gs coupling). Ipamorelin works through the calcium/phospholipase C pathway (via Gq coupling). These are biochemically independent cascades. When both pathways are activated simultaneously, the resulting GH release is greater than the sum of either alone — this is the pharmacological basis for the CJC-1295/Ipamorelin synergy.
Dose-dependent GH release: Ipamorelin produces GH release in a dose-dependent manner, with the response curve showing a clear plateau. Increasing the dose beyond the saturation point does not produce proportionally more GH but does increase the likelihood of side effects. This pharmacological ceiling is why standard dosing stays at 200–300 mcg — going higher provides diminishing returns.
Selectivity: Why It Matters
Ipamorelin's defining characteristic is selectivity — and understanding why this matters requires comparing it to what earlier GH secretagogues do wrong.
The Problem with GHRP-6 and GHRP-2
GHRP-6 and GHRP-2 are potent GH releasers, but they activate multiple hormonal pathways beyond GH:
Cortisol elevation. Cortisol is catabolic — it promotes tissue breakdown, fat storage (particularly visceral), and immune suppression. Elevating cortisol alongside GH partially counteracts the anabolic and lipolytic effects you're trying to achieve. It's like pressing the gas and brake simultaneously.
Prolactin elevation. Prolactin elevation can cause sexual dysfunction (reduced libido, erectile dysfunction in men), mood changes, and gynecomastia (breast tissue growth in men). These are significant quality-of-life side effects.
Appetite stimulation. GHRP-6 in particular produces intense hunger spikes that can undermine fat loss goals and make caloric control difficult.
Ipamorelin's Clean Profile
The Raun et al. (1998) study definitively demonstrated Ipamorelin's selectivity advantage. At doses producing GH release equivalent to GHRP-6:
| Hormone | GHRP-6 | GHRP-2 | Ipamorelin |
|---|---|---|---|
| GH | ↑↑↑ | ↑↑↑ | ↑↑↑ |
| Cortisol | ↑↑ | ↑ | No change |
| Prolactin | ↑↑ | ↑↑ | No change |
| ACTH | ↑↑ | ↑ | No change |
| Appetite | ↑↑↑ | ↑ | Mild / none |
This selectivity means Ipamorelin delivers GH elevation without the catabolic, endocrine-disrupting, or appetite-stimulating effects of older GHRPs. For anyone seeking GH optimization — whether for body recomposition, recovery, anti-aging, or sleep improvement — this cleaner profile is a decisive advantage.
MK-677 Comparison
MK-677 (Ibutamoren) is an oral ghrelin mimetic that's often compared to Ipamorelin. While convenient (pill vs injection), MK-677 has a ~24-hour half-life that creates sustained, non-pulsatile GH elevation, significant appetite stimulation, cortisol and prolactin elevation, and pronounced water retention. Its selectivity profile is closer to GHRP-6 than to Ipamorelin — the convenience of oral dosing comes at the cost of a much messier hormonal effect.
Human Clinical Data
Raun et al. (1998) — Selectivity Study
The foundational study establishing Ipamorelin's selectivity. Conducted in swine and rats, with key findings subsequently confirmed in human subjects. Demonstrated dose-dependent GH release with no significant effect on cortisol, prolactin, ACTH, or aldosterone at therapeutic doses.
Novo Nordisk Phase 2 Trials — Post-Operative Ileus
Novo Nordisk conducted Phase 2 clinical trials evaluating ipamorelin for accelerating recovery of bowel function after abdominal surgery (post-operative ileus). The trials enrolled hundreds of patients and established:
- Ipamorelin was well-tolerated at therapeutic doses
- GH release was consistent and dose-dependent
- No significant hormonal side effects (confirming animal data in humans)
- The post-operative ileus endpoint showed mixed results, leading Novo Nordisk to discontinue development for this indication
These trials provide the most substantial human safety dataset for ipamorelin, establishing tolerability in a clinical population at doses relevant to GH optimization.
Anderson et al. (2001) — Human Pharmacokinetics
Published pharmacokinetic data confirmed ipamorelin's ~2-hour half-life in humans and established the dose-response relationship for GH release. The study showed a clear plateau effect — doses beyond 1 mcg/kg did not produce proportionally more GH, supporting the standard 200–300 mcg dosing range for adults.
Dosing Protocols
Standard Protocol (Standalone)
| Parameter | Value |
|---|---|
| Dose | 200–300 mcg |
| Frequency | Once daily |
| Timing | Bedtime, empty stomach (1.5+ hours after food) |
| Route | Subcutaneous |
| Cycle length | 8–16 weeks |
| Off-cycle | 4–8 weeks |
Gold Standard Stack (With CJC-1295)
| Peptide | Dose | Timing |
|---|---|---|
| CJC-1295 (no DAC) | 100 mcg | Bedtime, empty stomach |
| Ipamorelin | 200–300 mcg | Bedtime, empty stomach (same syringe) |
Both drawn into one insulin syringe and injected together. The dual-pathway activation produces a synergistic GH pulse significantly larger than either compound alone.
→ Full stack guide: CJC-1295 + Ipamorelin Stack.
Twice-Daily Protocol (Enhanced)
| Dose | Timing |
|---|---|
| 100 mcg CJC + 200 mcg Ipa | Morning (fasted, before breakfast) |
| 100 mcg CJC + 200 mcg Ipa | Bedtime (1.5+ hours after dinner) |
Two GH pulses per day for users seeking maximum optimization.
Starting Dose (Conservative)
For first-time users: begin at 100–150 mcg for the first 1–2 weeks to assess tolerance, then increase to 200–300 mcg.
→ Calculate your exact reconstitution and dosing: Reconstitution Calculator.
Reconstitution & Administration
Ipamorelin arrives as a lyophilized powder, typically in 2 mg or 5 mg vials.
Reconstitution
- Swab vial stopper with alcohol
- Draw 2 mL bacteriostatic water into mixing syringe
- Direct water down the inside wall of the vial — never spray onto powder
- Swirl gently until dissolved (do not shake)
- Label with name, concentration, and date
- Refrigerate
Concentration Reference
| Vial Size | BAC Water | Concentration | 200 mcg = | 300 mcg = |
|---|---|---|---|---|
| 2 mg | 2 mL | 1 mg/mL | 20 units | 30 units |
| 5 mg | 2 mL | 2.5 mg/mL | 8 units | 12 units |
→ Full reconstitution walkthrough: How to Reconstitute Peptides.
→ Injection technique: How to Inject Peptides SubQ.
Side Effects & Safety
Common (Mild)
Head rush / facial flushing (10–15%). Brief sensation of warmth or flushing within 5–10 minutes of injection. Caused by the acute GH pulse. Resolves spontaneously. Generally considered a positive sign that the peptide is active.
Mild appetite increase. Some users report a modest increase in hunger, particularly in the first 1–2 weeks. This is typically far less pronounced than with GHRP-6 or MK-677 due to Ipamorelin's selectivity, but it can occur since ghrelin receptor activation does have some appetite-signaling component.
Injection site reactions. Minor redness or swelling at the injection site. Resolves quickly. Rotate sites between injections.
Water retention. Mild fluid retention in the first 1–2 weeks, typically 1–3 lbs. Resolves as the body adjusts.
Uncommon
Tingling in hands or feet. Occasionally reported. May indicate fluid retention pressing on peripheral nerves. Reduce dose if persistent.
Rare / Dose-Dependent
Joint stiffness or carpal tunnel symptoms. Only at high doses or in combination with other GH-elevating compounds. Reduce dose or extend cycling.
What Ipamorelin Does NOT Cause (At Therapeutic Doses)
- No significant cortisol elevation
- No significant prolactin elevation
- No testosterone or estrogen changes
- No thyroid axis disruption
- No HPTA suppression — no post-cycle therapy needed
Legal & Regulatory Status
Ipamorelin is not FDA-approved for any indication. Status by jurisdiction:
- United States: Available as a research chemical. Prescribed by some anti-aging and optimization clinics under 503A/503B compounding.
- Australia: Schedule 4 (prescription only). Available through TRT and anti-aging clinics.
- United Kingdom: Not licensed. Available through research suppliers.
- WADA: Prohibited (S2: Peptide Hormones, Growth Factors). Banned in all tested sport.
→ Full legal guide: Are Peptides Legal? 2026 Guide.
Ipamorelin vs Other GH Secretagogues
| Feature | Ipamorelin | GHRP-6 | GHRP-2 | MK-677 | Hexarelin |
|---|---|---|---|---|---|
| Route | SubQ | SubQ | SubQ | Oral | SubQ |
| Half-life | ~2 hours | ~20 min | ~25 min | ~24 hours | ~70 min |
| GH release | Strong | Strong | Strong | Moderate-Strong | Very Strong |
| Selectivity | Very high | Low | Moderate | Low | Low |
| Cortisol | No change | ↑↑ | ↑ | ↑ | ↑↑ |
| Prolactin | No change | ↑↑ | ↑↑ | ↑ | ↑↑ |
| Appetite | Mild | Intense | Moderate | Significant | Moderate |
| Water retention | Mild | Moderate | Moderate | Significant | Moderate |
| Desensitization | Slow | Moderate | Moderate | Slow | Fast |
Why Ipamorelin wins for most users: The selectivity advantage is not marginal — it's categorical. You get comparable GH release without the cortisol, prolactin, appetite, and water retention issues that make other GHRPs problematic for sustained use. The only trade-off is the need for injection (vs MK-677's oral convenience), which most users find acceptable.
→ Run any comparison: Comparison Tool.
Stacking Ipamorelin
Primary: CJC-1295 (no DAC) — Gold Standard
The most recommended combination. Dual-pathway synergy via GHRH + ghrelin receptor co-activation.
Recovery: + BPC-157 and/or TB-500
Adding repair peptides creates a comprehensive recovery protocol where elevated GH from the secretagogue stack supports the tissue repair driven by BPC-157/TB-500.
Fat Loss: + AOD-9604
AOD-9604's targeted lipolysis combined with Ipamorelin's GH-mediated fat metabolism for enhanced body recomposition.
→ Verify any combination: Interaction Checker.
→ Build protocols: Protocol Builder.
Frequently Asked Questions
How quickly does Ipamorelin work? GH release begins within 15–30 minutes of injection. Subjective effects (improved sleep) are typically noticed within the first week. Body composition changes become visible at weeks 6–10 with consistent use, training, and nutrition.
Can women use Ipamorelin? Yes. Ipamorelin does not affect sex hormones. Women can use identical dosing protocols and expect similar benefits in sleep, body composition, recovery, and skin quality.
Does Ipamorelin affect sleep? It enhances sleep. By amplifying the natural GH pulse that occurs during deep sleep, bedtime dosing of Ipamorelin frequently improves sleep depth and quality. Many users report more vivid dreams — a sign of enhanced REM and deep sleep cycling.
Is Ipamorelin better than HGH? Different tools for different situations. Ipamorelin is less expensive, maintains natural pulsatile release, requires no dose titration, and carries lower risk of the side effects associated with supraphysiological GH levels. HGH provides precise, controllable GH levels and has extensive clinical data. For most people pursuing general health optimization, Ipamorelin (with CJC-1295) offers a better risk/benefit ratio.
What if Ipamorelin isn't working? Check: (1) Are you fasting for 1.5+ hours before injection? Food blunts the response. (2) Is your peptide stored properly? Reconstituted peptides degrade without refrigeration. (3) Test IGF-1 levels at week 4–6 — if unchanged, suspect peptide quality. (4) Are you taking enough? Start at 200 mcg minimum; 100 mcg may be subtherapeutic for some individuals.
Related Tools & Articles
- Reconstitution Calculator — Calculate Ipamorelin dosing
- Protocol Builder — Build a GH optimization protocol
- Interaction Checker — Verify stack safety
- CJC-1295 + Ipamorelin Stack Guide
- CJC-1295 Complete Guide
- Best Peptides for Muscle Growth
Sources
- Raun, K. et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. PMID: 9849822
- Anderson, L. L. et al. (2001). Pharmacokinetics and pharmacodynamics of ipamorelin. Growth Hormone & IGF Research, 11(Suppl A), S24–S28.
- Bowers, C. Y. (2012). History to the discovery of ghrelin. Methods in Enzymology, 514, 3–32. PMID: 22975044
- Sigalos, J. T., & Pastuszak, A. W. (2018). The Safety and Efficacy of Growth Hormone Secretagogues. Sexual Medicine Reviews, 6(1), 45–53. PMID: 29174957
- Kojima, M. et al. (1999). Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature, 402(6762), 656–660. PMID: 10604470
- Nass, R. et al. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Annals of Internal Medicine, 149(9), 601–611. PMID: 18981485
Medical Disclaimer: This article is for educational and informational purposes only. Ipamorelin is not FDA-approved for any indication. Growth hormone optimization should be pursued under medical supervision with regular bloodwork monitoring.
© 2026 GreyPeptides.com — All rights reserved.
This article is for educational purposes only and does not constitute medical advice. Consult a licensed medical professional before considering any peptide therapy.